Introduction
High-grade osteosarcoma is a malignant bone tumor characterized by the production of osteoid. The highest incidence is in adolescent patients, with a second peak in patients older than 40 years (1). Despite wide-margin surgery and intensication of chemotherapeutic treatment, overall survival (OS) rates have reached a plateau at about 60% (24) . Novel administration modalities are needed, but data on critical biological mechanisms allowing the development of novel therapeutic agents are scarce for this relatively rare tumor. In addition to conventional chemotherapeutic agents, recent trials have explored immunostimulatory strategies. The ongoing EURAMOS-1 trial randomizes for treatment with IFN-α in patients with good histological response to neoadjuvant chemotherapy (5) . A recently published clinical trial has shown improved OS for osteosarcoma patients treated with the macrophage activating agent muramyl tripeptide (MTP) added to the standard chemotherapy regimen (6) . However, only limited information on macrophage inltration and activation in osteosarcoma is available (7) .
Tumor-associated macrophages (TAM) may promote tumorigenesis through immunosuppression, expression of matrix-degrading proteins and support of angiogenesis. In numerous cancer types, high numbers of M2 or`alternatively activated' TAMs are associated with a worse prognosis (813). M2 macrophages have important functions in wound healing and angiogenesis, express high levels of the immunosuppressive cytokines interleukin (IL)-10 and TGF-β, and express scavenger receptors such as CD163 (14, 15) .`Classical activation' of macrophages by IFN-γ or microbial products results in polarization toward M1-type macrophages. M1 macrophages express high levels of proinammatory cytokines such as IL-12, IL-1, and IL-6 and have potent antitumor ecacy, both by reactive oxygen species and cytokine-induced cytotoxicity and by induction of natural killer (NK) and T cell activity (16) . Rarely, high numbers of TAMs are associated with better prognosis (17, 18) . In these cases, TAMs are presumably polarized toward an M1 phenotype, although macrophage subtypes were not reported in these two studies. Alternatively, macrophages may directly phagocytose tumor cells, as has been shown in acute myeloid leukemia (19) .
To investigate the role of stroma and stromatumor interactions important in metastasis of osteosarcoma, we investigated the development of metastasis by studying tumor cells and their stromal context. By using genome-wide expression analysis, we showed that high expression of macrophage-associated genes in pretreatment biopsies was associated with a lower risk of developing metastases. In addition, we quantied and characterized TAMs in two independent cohorts, including pretreatment biopsies, postchemotherapy resections, and metastatic lesions. In contrast to the tumor-supporting role for TAMs in most epithelial tumor types, higher numbers of inltrating TAMs correlated with better survival in osteosarcoma. Our ndings suggest that macrophages have direct or indirect antiosteosarcoma activity and provide a possible explanation for the benecial eect of treatment with macrophage activating agents in osteosarcoma.
Materials and methods

Patient cohorts
Genome-wide expression proling was performed on snap-frozen pretreatment diagnostic biopsies containing viable tumor material of 53 resectable high-grade osteosarcoma patients from the EuroBoNet consortium (www.eurobonet.eu; cohort 1). For immunohistochemical validation, a tissue microarray containing 145 formalin-xed paran-embedded (FFPE) samples of 88 consecutive high-grade osteosarcoma patients with primary resectable disease (cohort 2) and 29 FFPE samples of a cohort of 20 consecutive high-grade osteosarcoma patients with resectable disease were used (cohort 3), including material from pretreatment biopsies, postchemotherapy resections, and metastatic lesions (20) .
Clinicopathological details can be found in Supplemental Table S1 (available online (21)).
All biological material was handled in a coded fashion. Ethical guidelines of the individual European partners were followed and samples and clinical data were stored in the EuroBoNet biobank. The 19 osteosarcoma cell lines 143B, HAL, HOS, IOR/MOS, IOR/OS10, IOR/OS14,   IOR/OS15, IOR/OS18, IOR/OS9, IOR/SARG, KPD, MG-63, MHM, MNNG-HOS, OHS, OSA, SAOS-2, U-2 OS, and ZK-58 were maintained in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (Invitrogen) as previously described (22).
Cell lines
RNA isolation, cDNA synthesis, cRNA amplication, and Illumina Human-6 v2.0 Expression BeadChip hybridization Osteosarcoma tissue was snap-frozen in 2-methylbutane (Sigma-Aldrich) and stored at 70
• C. By using a cryostat, 20mm sections from each block were cut and stained with hematoxylin and eosin to ensure at least 70% tumor content and viability. RNA was isolated with TRIzol (Invitrogen), followed by RNA cleanup using the QIAGEN Rneasy mini kit with on-column DNase treatment. RNA quality and concentration were measured using an Agilent 2100 Bioanalyzer and Nanodrop ND-1000 (Thermo Fisher Scientic), respectively. Synthesis of cDNA, cRNA amplication, and hybridization of cRNA onto the Illumina Human-6 v2.0 Expression BeadChips was carried out as per manufacturer's instructions.
Reverse transcriptase quantative PCR
Reverse transcriptase quantative PCR (qPCR) analysis of selected target genes was performed as previously described (23) . Each experiment was conducted in duplicate by using an automated liquid-handling system (Tecan, Genesis RSP 100). Data were normalized by geometric mean expression levels of 3 reference genes, i.e. SRPR, CAPNS1, and TBP using geNorm (medgen.ugent.be/~jvdesomp/genorm/). Primer sequences can be found in Supplemental Table S2 (available online (21)).
Enzymatic and uorescent immunostainings
Enzymatic and uorescent immunostainings were performed on 4mm sections of FFPE tissue as previously described (20) . Details regarding antibodies and procedures can be found in Supplemental Table S3 (available online (21)). In case of double immunohistochemistry (IHC), incubation with anti-CD45 and development with DAB+ (Dako) occurred rst, followed by a second antigen retrieval before incubation with either anti-CD163 or anti-HLA-DRα and development using the alkaline phosphatase substrate Vector Blue 
Microarray data analysis
Gene expression data were exported from BeadStudio version 3.1.3.0 (Illumina) in GeneSpring probe prole format and processed and analyzed using the statistical language R (24). As Illumina identiers are not stable and consistent between dierent chip versions, raw oligonucleotide sequences were converted to nuIDs (25) . Data were transformed using the variance stabilizing transformation algorithm to take advantage of the large number of technical replicates available on the Illumina BeadChips (26) . Transformed data were normalized using robust spline normalization, an algorithm combining features of quantile and loess normalization, specically designed to normalize variancestabilized data. All microarray data processing was carried out by Bioconductor package lumi (27, 28) . Quality control was performed using Bioconductor package arrayQualityMetrics (29) . MIAME (minimum information about a microarray experiment) compliant data have been deposited in the GEO database (www.ncbi.nlm.nih.gov/geo/, accession number GSE21257).
Statistical analysis
Dierential expression between patients who did (n = 34) and did not (n = 19) develop metastases within 5 years from diagnosis of the primary tumor was determined using linear models for microarray data (LIMMA (30) and an additional 25% of the upregulated probes corresponded to genes with other immunological functions, such as cytokine production and phagocytosis. Four genes were selected for validation of the microarray data using qPCR: CD14, HLA-DRA, CLEC5A, and FCGR2A. Expression levels as determined by qPCR correlated well with expression levels obtained by microarray analysis (Supplemental Figure S1 (available online (21))).
Metastases-free survival curves of the same cohort, generated using median expression of the probe of interest as a cuto determining low and high expression, are shown in Macrophage numbers in diagnostic biopsies may predict histological response to chemotherapy and macrophage number increases following chemotherapy treatment
There was a trend for high macrophage count (highest three quartiles or more than 12 CD14-positive cells per tissue array core) in prechemotherapy diagnostic biopsies of the primary tumor to predict for good histological response to neoadjuvant chemotherapy (dened as more than 90% nonvital tumor tissue upon nal resection), since 46% of patients with high macrophage numbers and 18% of patients with low macrophage numbers had a good histological response (cohort 2; χ 2 = 0.09). The prognostic benet of macrophage counts in osteosarcoma was not independent of histological response using
Cox proportional hazard analysis. Macrophage numbers were higher in postchemotherapy resections of the primary tumor than in prechemotherapy biopsies (Supplemental Figure   S4 (available online (21))). Moreover, gene expression analysis showed upregulation of macrophage-associated probes in postchemotherapy resections (n = 4) as compared with prechemotherapy biopsies (n = 79, data not shown). 
Discussion
OS of high-grade osteosarcoma patients with resectable metastatic disease is poor at about 20% (31) . Mechanisms for the development of metastases in osteosarcoma are elusive. To identify genes that play a role in this process, we performed genome-wide expression proling on prechemotherapy biopsies of osteosarcoma patients. We compared patients who developed clinically detectable metastases within 5 years with patients who did not develop metastases within this time frame (cohort 1). About 20% of genes overexpressed in patients without metastases were macrophage-associated, whereas an additional 25% of genes had other immunological functions (e.g. in phagocytosis, complement activation or cytokine production and response) but could still be attributed to macrophages (Table 1 and Supplemental Table S4 (available online ( TAMs that were identied in this study in osteosarcoma had both M1 and M2 characteristics. The expression of CD163 and the association with angiogenesis are M2 characteristics (32, 36) . Some of the DE genes, such as MSR1 and MS4A6A are specic for M2 macrophages in vitro (37) . Others, such as the proinammatory cytokine IL1B, are more indicative of an M1 phenotype (16) . How macrophages inhibit osteosarcoma metastasis and whether a balance between M1-and M2-type functions is responsible is unknown.
In a multivariate regression model, the survival benet of high TAM numbers was at least partly dependent on histological response to chemotherapy. Chemotherapy can cause`immunogenic cell death' of cancer cells, resulting in the release of endogenous danger signals (38, 39) . Previous genome-wide expression proling studies in osteosarcoma focused on identifying genes that predict histological response to neoadjuvant chemotherapy (4346). As a consequence, the importance of macrophages in controlling metastases was not recognized. However, we previously compared gene expression proles of osteosarcoma biopsies and cultured mesenchymal stem cells and determined which genes are expressed by tumor stroma and not by tumor cells (47) . There is a considerable overlap between the stromal genes identied in our previous study and the macrophage-associated genes identied in the present study (including HLA class II genes as the most prevalent DE group of genes and the macrophage-associated genes MSR1, MS4A6A, and FCGR2A).
In conclusion, we showed the presence and clinical signicance of TAMs in pretreatment samples of high-grade osteosarcoma. TAMs in osteosarcoma are a heterogeneous cell population with both M1 antitumor and M2 protumor characteristics. Although the exact mechanism by which macrophages exert their antimetastatic functions is still unknown, this study provides an important biological rationale for the treatment of osteosarcoma patients with macrophage activating agents.
